Noven Pharmaceuticals, Inc. is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing, and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery.
Over 300 Noven colleagues are working to advance our business and benefit patients at locations in Miami, Florida and Jersey City, New Jersey. We are a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., the world’s largest manufacturer of transdermal patches, and we serve as Hisamitsu's platform for US prescription pharmaceuticals, helping Hisamitsu bring the benefits of patch therapy to the world.
Noven maintains state-of-the art, FDA-approved transdermal manufacturing facilities in Miami with capacity to produce several hundred million patches per year. These facilities are also approved by the US DEA (Drug Enforcement Agency) for the production of controlled substances.
Noven’s commercialized transdermal products include XELSTRYMTM (dextroamphetamine) transdermal system, CII, the first and only patch approved for the treatment of ADHD in children and adolescents; SECUADO® (asenapine) transdermal system, the first and only patch approved for the treatment of schizophrenia in adults in the United States; MINIVELLE® (estradiol transdermal system), the planet’s smallest estrogen patch; COMBIPATCH® (estradiol/norethindrone acetate transdermal system), the first approved combination (two-drug) patch; DAYTRANA® (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD in children and adolescents. Noven's commercialized products are marketed through Noven Therapeutics, LLC.
Noven’s product development pipeline includes a range of prescription transdermal products that utilize Noven’s advanced transdermal delivery technology. For a summary of our disclosed pipeline, click here.